SCM
FOLD

Soleus Capital Management’s Amicus Therapeutics FOLD Stock Holding History

Soleus Capital Management’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,207,284
Closed -$74.2M – 103
2025
Q4 		$74.2M Buy
5,207,284
+517,284
+11% +$5.08M 2.74% 11
2025
Q3 		$37M Buy
+4,690,000
New +$33.4M 1.86% 17
2024
Q2 		– Sell
-57,966
Closed -$683K – 100
2024
Q1 		$683K Buy
+57,966
New +$741K 0.05% 86
2020
Q3 		– Sell
-127,300
Closed -$1.92M – 66
2020
Q2 		$1.92M Buy
127,300
+55,300
+77% +$674K 1.09% 29
2020
Q1 		$665K Sell
72,000
-116,800
-62% -$1.11M 0.77% 30
2019
Q4 		$1.84M Buy
+188,800
New +$1.73M 1.77% 22

Other funds holding FOLD

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Soleus Capital Management's FOLD Position: Q1 2026 in Review

Soleus Capital Management sold out of Amicus Therapeutics (FOLD) in Q1 2026, closing a stake of 5,207,284 shares — an estimated $74.2M sold.

Soleus Capital Management first reported a position in FOLD in Q4 2019 and held it in 6 quarters. The position peaked at $74.2M in Q4 2025. 298 funds tracked by Wall St. Rank hold FOLD as of Q1 2026.

  • Soleus Capital Management reported no remaining Amicus Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Soleus Capital Management sold 5,207,284 Amicus Therapeutics shares in Q1 2026, an estimated $74.2M.
  • Soleus Capital Management first reported a position in Amicus Therapeutics in Q4 2019 and held it in 6 quarters.
  • Soleus Capital Management's Amicus Therapeutics position peaked at $74.2M in Q4 2025.
  • 298 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2026.

Based on Soleus Capital Management's 13F filing for Q1 2026, filed 14 May 2026.